Evidence map›Paper›PMID 34001007›Full record

ArticleBMC bioinformatics2021

Learning curves for drug response prediction in cancer cell lines.

Alexander Partin, Thomas Brettin, Yvonne A Evrard, Yitan Zhu, Hyunseung Yoo, Fangfang Xia, Songhao Jiang, Austin Clyde, Maulik Shukla, Michael Fonstein and 2 more

Abstract read
In one paragraph

Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexander PartinDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA. apartin@anl.gov.ORCID http://orcid.org/0000-0002-9279-9213
Thomas BrettinUniversity of Chicago Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, USA.
Yvonne A EvrardFrederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
Yitan ZhuDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA.
Hyunseung YooDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA.
Fangfang XiaDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA.
Songhao JiangDepartment of Computer Science, University of Chicago, Chicago, IL, USA.
Austin ClydeDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA.
Maulik ShuklaDivision of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA.
Michael FonsteinBiosciences Division, Argonne National Laboratory, Lemont, IL, USA.
James H DoroshowDivision of Cancer Therapeutics and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Rick L StevensComputing, Environment and Life Sciences, Argonne National Laboratory, Lemont, IL, USA.

Funding

Phase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0M
6 · The paper itself

Abstract

backgroundMotivated by the size and availability of cell line drug sensitivity data, researchers have been developing machine learning (ML) models for predicting drug response to advance cancer treatment. As drug sensitivity studies continue generating drug response data, a common question is whether the generalization performance of existing prediction models can be further improved with more training data.

methodsWe utilize empirical learning curves for evaluating and comparing the data scaling properties of two neural networks (NNs) and two gradient boosting decision tree (GBDT) models trained on four cell line drug screening datasets. The learning curves are accurately fitted to a power law model, providing a framework for assessing the data scaling behavior of these models.

resultsThe curves demonstrate that no single model dominates in terms of prediction performance across all datasets and training sizes, thus suggesting that the actual shape of these curves depends on the unique pair of an ML model and a dataset. The multi-input NN (mNN), in which gene expressions of cancer cells and molecular drug descriptors are input into separate subnetworks, outperforms a single-input NN (sNN), where the cell and drug features are concatenated for the input layer. In contrast, a GBDT with hyperparameter tuning exhibits superior performance as compared with both NNs at the lower range of training set sizes for two of the tested datasets, whereas the mNN consistently performs better at the higher range of training sizes. Moreover, the trajectory of the curves suggests that increasing the sample size is expected to further improve prediction scores of both NNs. These observations demonstrate the benefit of using learning curves to evaluate prediction models, providing a broader perspective on the overall data scaling characteristics.

conclusionsA fitted power law learning curve provides a forward-looking metric for analyzing prediction performance and can serve as a co-design tool to guide experimental biologists and computational scientists in the design of future experiments in prospective research studies.

Indexed as

NeoplasmsPharmaceutical PreparationsCell LineLearning CurveMachine LearningProspective StudiesPharmaceutical PreparationsCell lineDeep learningDrug response predictionLearning curveMachine learningPower law

Identifiers

PMID34001007
PMCPMC8130157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.